CHEPLAPHARM Arzneimittel GmbH


This section provides relevant information as well as ongoing and timely updates on the strategic and operative success stories of our steadily growing Company.


Your contact persons

Jens Remmers

Head of Treasury & Investor Relations

IR center of information

Financial Reports

1st December 2022
Earnings Call Q3 2022 Results
29th November 2022
Publication Quarterly Report Q3 2022
1st September 2022
Earnings Call H1 2022 Results
29th August 2022
Publication 1st Half-Year Report 2022
2nd June 2022
Investor Call Quarterly Report Q1 2022
31st May 2022
Publication Quarterly Report Q1 2022
10th May 2022
Investor Call Full Financial Year 2021 audited
29th April 2022
Publication Full Financial Year 2021 audited
30th November 2021
Investor Call Quarterly Report Q3 2021
19th November 2021
Publication Quarterly Report Q3 2021
24th August 2021
Investor Call Quarterly Report Q2 2021
20th August 2021
Publication Quarterly Report Q2 2021
Find out how you can benefit


The latest from CHEPLAPHARM

CHEPLAPHARM acquires two product portfolios

Greifswald, 06/22/2020

The first bundle of four molecules and eight related brands, focusing on the two main therapeutic areas uro-oncology and gynaecology, was bought in October 2019. The APIs of the referring products are Buserelin, Oxybutynin, Nilutamide and Gonadorelin.

"This investment will enhance the diversification of our product portfolio”, said CHEPLAPHARM’s CEO Sebastian F. Braun. “Furthermore, this agreement matches perfectly with our internationally oriented business strategy."

The second bundle was bought at the end of May 2020. The package includes 11 molecules and 17 related brands, focusing on the therapeutic areas cardiology and intensive care, and are on sale in about 25 countries. The main APIs are Betaxolol and Heparin-Calcium. Five molecules of this portfolio are part of the World Health Organization list of essential medicines. Until all acquired marketing authorizations in the respective countries have been transferred to CHEPLAPHARM, the production and distribution will be ensured by the seller.

Edeltraud Lafer, Chief Operating Officer at CHEPLAPHARM concludes: "These recent acquisitions will help ensure continued patient access to multiple essential medicines in many countries."

Press office:
CHEPLAPHARM Arzneimittel GmbH | Ziegelhof 24 | 17489 Greifswald | presse(at)

Investor Relations topics

Back to top expand_less